Latest Articles

Publication Date
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - MSN

Repare Therapeutics eyes Phase III cancer study after Mythic trial success MSN

Published: Jan. 14, 2025, 11:17 a.m.
Engineering nanosystems for regulating reproductive health in women.

Reproductive health-related diseases have a significant impact on the well-being of millions of women worldwide, severely compromising their quality of life. Women encounter unique challenges in terms of reproductive health, …

Published: Jan. 1, 2025, midnight
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - Yahoo Finance

Repare Therapeutics eyes Phase III cancer study after Mythic trial success Yahoo Finance

Published: Dec. 13, 2024, 3:28 p.m.
Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - CRISPR Medicine News

Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial CRISPR Medicine News

Published: Dec. 13, 2024, 12:56 p.m.
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - BioSpace

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial BioSpace

Published: Dec. 12, 2024, 11:25 p.m.
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis Seeking Alpha

Published: Dec. 12, 2024, 8:25 p.m.
Karyopharm Therapeutics Provides Regulatory Update on Endometrial Cancer ProgramOn December 3, 2024, Karyopharm Therapeutics Inc. released a press statement outlining a regulatory update on its endometrial cancer program. This update comes in li - Defense World

Karyopharm Therapeutics Provides Regulatory Update on Endometrial Cancer ProgramOn December 3, 2024, Karyopharm Therapeutics Inc. released a press statement outlining a regulatory update on its endometrial cancer program. This update …

Published: Dec. 4, 2024, 8:10 a.m.
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - Investor Relations | Karyopharm Therapeutics

Karyopharm Therapeutics Provides Endometrial Cancer Program Update Investor Relations | Karyopharm Therapeutics

Published: Dec. 3, 2024, 12:01 p.m.
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - Kilgore News Herald

Karyopharm Therapeutics Provides Endometrial Cancer Program Update Kilgore News Herald

Published: Dec. 3, 2024, noon
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - PR Newswire

Karyopharm Therapeutics Provides Endometrial Cancer Program Update PR Newswire

Published: Dec. 3, 2024, noon
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!